INDP Stock Forecast: Indaptus Therapeutics, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 25 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Indaptus Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (75): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (20): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
INDP stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on INDP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Nov 2024 | Maxim Group | Maintains | Buy | $8.00 → $5.00 |
| 16 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Apr 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Sept 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Mar 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Mar 2023 | HC Wainwright & Co. | Reiterates | Overweight | — |
| 8 Feb 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 Jan 2022 | HC Wainwright & Co. | Assumes | Buy | $15 |
| 19 Oct 2021 | Maxim Group | Upgrade | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
INDP appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
INDP vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Indaptus Therapeutics, Inc. returned +61.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
INDP analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 1.9×
- EV / EBITDA
- —
Cheaper than 44% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −318.0%
- Return on assets
- −98.1%
- Dividend yield
- —
Higher than 5% of US stocks
Higher than 3% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Indaptus Therapeutics, Inc. has a market value of $433.2M and an enterprise value of $410.8M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$15.4M.
Free cash flow in the twelve months to 30 June 2026: −$14.7M.
Indaptus Therapeutics, Inc. employs 5 people.
Data provided by Twelve Data
INDP and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at INDP’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Indaptus Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about INDP
How does Ticker Nerd's model rank INDP?
As at 21 Nov 2026, Indaptus Therapeutics, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (75 of 100).
What is the INDP stock forecast for 2030?
No analyst covering Indaptus Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INDP are extrapolating price history, which says nothing about the business.
How has INDP stock performed over the past year?
Indaptus Therapeutics, Inc. returned +61.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Indaptus Therapeutics, Inc. do?
Indaptus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing immunotherapy products for cancer and viral infections. The company’s current work centers on its Decoy platform, a proprietary system designed to activate multiple components of the innate and adaptive immune system while aiming to reduce systemic toxicity.
About Indaptus Therapeutics, Inc.
Indaptus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing immunotherapy products for cancer and viral infections. The company’s current work centers on its Decoy platform, a proprietary system designed to activate multiple components of the innate and adaptive immune system while aiming to reduce systemic toxicity. Its lead candidate, Decoy20, is being developed for a range of oncology and infectious disease applications, including solid tumors and chronic viral infections. Indaptus Therapeutics Inc. operates in the biopharmaceutical sector, where it contributes to research-driven drug development with an emphasis on novel immune-activating approaches. Based in New York, the company is primarily engaged in preclinical and clinical-stage development activities rather than commercial product sales.
CEO Mr. Junyi Dai · 5 employees · United States · https://indaptusrx.com